imatinib mesylate has been researched along with Myositis Ossificans in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Al Mukaddam, M; Andolina, JR; Hsiao, EC; Kaplan, FS; Mancilla, EE; Pignolo, RJ; Rocke, DM; Siegel, DM; Teachey, DT | 1 |
| Adamson, PC; Andolina, JR; Ebb, DH; Finklestein, JZ; Hsiao, E; Jacobs, B; Kaplan, FS; Keen, R; Pignolo, RJ; Siegel, DM; Teachey, DT; Whitehead, B | 1 |
| Mudry, P; Neradil, J; Noskova, H; Rohleder, O; Slaby, O; Sterba, J | 1 |
3 other study(ies) available for imatinib mesylate and Myositis Ossificans
| Article | Year |
|---|---|
Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva.
Topics: Activin Receptors, Type I; Activities of Daily Living; Child; Humans; Imatinib Mesylate; Myositis Ossificans; Ossification, Heterotopic | 2021 |
Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.
Topics: Activin Receptors, Type I; Adolescent; Bone Morphogenetic Proteins; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Male; Mutation; Myositis Ossificans; Ossification, Heterotopic; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2018 |
Letter to Editor: F.S. Kaplan, et al., Early clinical observations on the use of imatinibmesylate in FOP: A report of seven cases, Bone (2017).
Topics: Bone and Bones; Female; Humans; Imatinib Mesylate; Infant; Mutation; Myositis Ossificans | 2018 |